Expert Statement on the Single-Agent Use of Inhaled Bronchodilator in the Treatment of Stable Mild-Moderate Chronic Obstructive Pulmonary Disease
Riesco Miranda JA (1), Alcázar B (2), Alfageme I (3), Casanova C (4), Celli B (5), de-Torres JP (6), Jiménez Ruiz CA (7).
(1) Servicio de Neumología, Hospital San Pedro de Alcántara, Cáceres, España; Centro de Investigación Biomédica en Red, CIBERES, España. (2) Servicio de Neumología, Hospital de Alta Resolución de Loja, Loja, Granada, España.
(3) Servicio de Neumología, Hospital Universitario de Valme, Sevilla, España.
(4) Servicio de Neumología-Unidad de Investigación, Hospital Universitario Nuestra Señora de La Candelaria, Santa Cruz de Tenerife, España.
(5) Servicio de Neumología, Brigham and Women's Hospital, Boston, Estados Unidos de América.
(6) Servicio de Neumología, Clínica Universidad de Navarra, Pamplona, España. 7
Unidad Especializada en Tabaquismo de la Comunidad de Madrid, Madrid, España.
To describe the evidence- and experience-based expert consensus on the use of single-agent bronchodilators in patients with stable mild-moderate chronic obstructive pulmonary disease (COPD).
Using Delphi methodology, a panel of 7 respiratory medicine experts was established, who, in the first nominal group meeting defined the scope, users, and document sections.
The panel drew up 14 questions on the use of single-agent bronchodilators in patients with mild-moderate stable COPD to be answered with a systematic review of the literature. The results of the review were discussed in a second nominal group meeting and 17 statements were generated.
Agreement/disagreement with the statements was tested among16 different experts including respiratory medicine experts and primary care physicians. Statements were scored from1 (total disagreement) to10 (total agreement). Agreement was considered if at least 70% voted ≥7. The level of evidence and grade of recommendation of the systematic literature review was assessed using the Oxford Centre for Evidence-based Medicine levels.
A total of 12 of the 17 statements were selected. Specific statements were generated on different profiles of patients with stable mild-moderate COPD in whom single-agent bronchodilators could be prescribed.
These statements on the use of single-agent bronchodilators might improve the outcomes and prognosis of patients with stable mild-moderate COPD.
CITATION Arch Bronconeumol. 2017 May 8. pii: S0300-2896(17)30088-1. doi: 10.1016/j.arbres.2017.03.022